BioSpace News Archive

Exact Sciences Corp. announced that the company plans to release its fourth quarter 2020 financial results after the close of the U.S. financial markets on February 16, 2021.

Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

SIFI, a leading ophthalmic company, announced the publication of clinical results from its Phase I trial of polihexanide in healthy volunteers.

A group of 37 medical and radiation oncologists, along with a robust staff of cancer care providers, led by Drs. Bruno S. Fang and Edward J. Licitra, who currently comprise the “Central Jersey Division” of Regional Cancer Care Associates, are forming Astera Cancer Care, an independent and physician-owned multi-specialty community oncology practice serving 12,000 new patients annually in Central New Jersey.

BWX Technologies, Inc. (NYSE: BWXT) today announced that its subsidiary BWXT ITG Canada, Inc., a nuclear medicine company, has been renamed BWXT Medical Ltd. (BWXT Medical), in order to better align with the company’s products, customer base and strategy.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Stephen “Steve” L. Mayo, professor, California Institute of Technology, will join the company’s Board of Directors effective March 15, 2021

DuPont announced it is completing the merger of IFF and Nutrition & Biosciences.

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administration’s (“FDA”) approval of the Company’s prior approval supplement application (“PAS”).

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report fourth quarter and full-year 2020 financial results on Monday, February 22, 2021

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the FDA has lifted the hold and the AT-007 ACTION-Galactosemia Kids pediatric clinical study will resume effective immediately.